Clinical Trial Update: Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating titrated oral tolvaptan (15-60 mg QD) on cognitive and neurological function in elderly patients with hyponatremia; results posted afte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia

Drugs mentioned

• Samsca (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Hyponatremia | Phase 3 | Status: COMPLETED | Results posted: 2011-04-28